Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful and statistically significant reductions in body weight with continued weight loss beyond 36 weeks, up to 16.2% during the open-label extension Aleniglipron safety profile reflects well-known GI-relate